From best to good: can we "right-size" approaches to reducing healthcare-associated infections?
Kirkland
Kathryn B
KB
Section of Infectious Disease and International Health, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA. kathy.kirkland@dartmouth.edu
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000494:pharmacology; D001494:Baths; D002353:Carrier State / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control; D002710:Chlorhexidine / Q000008:administration & dosage; D003428:Cross Infection / Q000453:epidemiology* / Q000382:microbiology / Q000517:prevention & control*; D006801:Humans; D017053:Infection Control / Q000379:methods*; D007362:Intensive Care Units; D016712:Mupirocin / Q000008:administration & dosage; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects
D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D016712:Mupirocin; D002710:Chlorhexidine